Equities researchers at StockNews.com initiated coverage on shares of 22nd Century Group (NASDAQ:XXII – Get Free Report) in a research report issued on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.
22nd Century Group Stock Performance
NASDAQ XXII opened at $0.10 on Wednesday. 22nd Century Group has a 12 month low of $0.09 and a 12 month high of $6.56. The stock’s fifty day moving average price is $0.19 and its 200-day moving average price is $0.64. The stock has a market cap of $4.66 million, a P/E ratio of 0.00 and a beta of 1.45.
22nd Century Group (NASDAQ:XXII – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. The firm had revenue of $7.95 million during the quarter. 22nd Century Group had a negative return on equity of 380.39% and a negative net margin of 275.12%.
Institutional Investors Weigh In On 22nd Century Group
About 22nd Century Group
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
Featured Stories
- Five stocks we like better than 22nd Century Group
- What is a Bond Market Holiday? How to Invest and Trade
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.